Sales and Marketing

Showing 15 posts of 11527 posts found.

Eli Lilly drops development of diabetes drug in Phase III

April 19, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial

US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …

FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder

April 18, 2016 Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease

Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …

Novo unveils new research grant to mark World Haemophilia Day

April 18, 2016 Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day

Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …

British Biosimilars Association launches in UK

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Napp, bba, bgma, british biosimilars association

A new industry body, the British Biosimilars Association, has been formally launched today with the sole focus of increasing the …

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…

April 18, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market

Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …

Sticking the boot in

April 18, 2016 Sales and Marketing Boots, Cost, Guardian, NHS, prescribing, scandal, unfair

A recent exposé has shone a light on the practices allegedly enforced at the nation’s largest pharmacy. So what exactly …

Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics

April 18, 2016 Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology

Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …

Roche sues Intas Pharma over patent dispute in India

April 18, 2016 Medical Communications, Sales and Marketing India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent

Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, …

NICE recommends PTC Therapeutics’ Translarna to treat Duchenne muscular dystrophy

April 18, 2016 Sales and Marketing DMD, Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, regulation

Shares in drug maker PTC Therapeutics (Nasdaq: PTCT) jumped after the National Institute for Health and Care Excellence (NICE) backed …

Shire announces new $400 million biologics plant and 400 new jobs in Ireland

April 18, 2016 Manufacturing and Production, Sales and Marketing IDA, Ireland, Shire, investment, meath, shire pharmaceuticals

Shire Pharmaceuticals has announced the expansion of its Irish operations with a new $400 million biologics plant set to deliver …

AstraZeneca hold internal talks for Medivation takeover – reports

April 18, 2016 Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover

AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …

US annual spending on drugs rose 12.2% in 2015 – IMS

April 15, 2016 Medical Communications, Research and Development, Sales and Marketing IMS Health, drug spending

The total US spending on prescription drugs rose 12.2% to almost $425 billion in 2015 on the back of new …

Synta Pharmaceuticals announces merger with Madrigal

April 15, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger

Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …

Merck says US FDA to review its Keytruda for head & neck cancer

April 14, 2016 Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda

The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …

Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials

April 14, 2016 Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier

US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …
The Gateway to Local Adoption Series

Latest content